96.91
+0.01(+0.01%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
260
First IPO Date
May 19, 2016
| Name | Title | Pay | Year Born |
| Sven Ante Lundberg | Chief Executive Officer, President & Executive Director | 1.24M | 1963 |
| Jan van de Winkel | CEO & Executive Director | 0 | N/A |
| Cornelis Adriaan de Kruif | Chief Technology Officer & Executive Vice President | 380,432 | 1964 |
| Fabian Zohren | Chief Medical Officer | 637,930 | 1976 |
| Gregory D. Perry | Chief Financial Officer | 757,509 | 1960 |
| Peter Silverman | EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer & Head of US Legal | 895,170 | 1978 |
| Cecilia Anna Wilhelmina Geuijen | Chief Scientific Officer & Senior Vice President | 0 | N/A |
| Hennie Hoogenboom | Co-Founder and Scientific Advisor | 0 | N/A |
| Harry Shuman | Chief Accounting Officer | 0 | N/A |
| Kathleen Farren | Director of IR & Corporate Communications Officer | 0 | N/A |
| Sherri Spear | Senior Vice President of Investor Relations & Strategic Communications | 0 | N/A |
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.